Unibio USA ApS: Financial statements 2021
CVR: 38179845
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Unibio USA ApS (CVR 38179845) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -15,000 and a net result of DKK -12,000 compared with DKK -11,000 the year before. Equity in the 2021 report amounted to DKK 72,000. The solvency ratio was 73.5%.
- Gross Profit
- DKK -15,000
- Profit/Loss
- DKK -12,000
- Equity
- DKK 72,000
- Total Assets
- DKK 98,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -15K | -12K | 72K | 0 |
| 2020 | - | -14K | -11K | 8K | 0 |
| 2019 | - | -15K | -12K | 19K | 0 |
| 2018 | - | -15K | -12K | 31K | 0 |
Official annual report
Find more companies like Unibio USA ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
Unibio USA ApS has published its annual report for 2020. Gross profit came to DKK -14,000, and the net result was DKK -11,000.
As of June 1, 2021, Søren Olrik Eklund is registered as adm. dir. of Unibio USA ApS.
As of May 31, 2021, Henrik Busch-Larsen has stepped down as adm. dir. of Unibio USA ApS.
About Unibio USA ApS
Unibio USA ApS is a Danish company of the type Anpartsselskab based in Roskilde, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of David Richard Henstrom and Søren Olrik Eklund. The company is owned by UNIBIO A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a net result of DKK -20,000 compared with DKK -26,000 the year before. Equity in the 2025 report amounted to DKK 25,000.